We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Maternal Lipid Profile Tied to Pediatric CHD Risk

By LabMedica International staff writers
Posted on 25 Sep 2021
Congenital heart disease (CHD among live births, is the major form of birth defect and the leading cause of childhood mortality with an incidence of 9.1‰. More...
The occurrence of CHD is caused by many factors.

With the improvement in living standards and an increasing number of women with advanced maternal age, there is an increase in the prevalence of chronic metabolic diseases, such as obesity, diabetes, hypertension, and hyperlipidemia, among pregnant women.

Clinical Scientists at the Children's Hospital of Fudan University (Shanghai, China) carried out a single-center case–control study that included 230 mothers of offspring with CHD and 381 without CHD. Maternal lipid levels were determined on fasting blood samples taken in the first trimester. Relevant demographic and clinical data were extracted from the medical records. Maternal lipid profile was compared between the two groups, and regression analysis was performed to evaluate the association between lipid profile and CHD risk in offspring.

Fasting peripheral blood samples were collected between eight and 14 weeks of gestation. Folic acid, vitamin B12, thyroid abnormality, homocysteine (Hcy), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), free fatty acid, Apolipoprotein-A1 (Apo-A1), Apolipoprotein-B (Apo-B), fasting blood glucose, and hemoglobin A1c (HbA1c) were all measured. TG, TC, HDL-C, LDL-C, free fatty acid, Apo-A1, Apo-B, and fasting blood glucose were analyzed by an automatic biochemical analyzer (Hitachi 7180, Tokyo, Japan) using commercially available kits. Folic acid and vitamin B12 were measured using the Architect i2000chemiluminescence immunoassay analyzer (Abbott, Lake Forest, IL, USA). Serum Hcy measurements were carried out by Liquid Chromatography Coupled to Tandem Mass Spectrometry (LC/MS/MS) using an API 3000 LC/MS/MS system (Applied Biosystems, Waltham, MA, USA).

The investigators reported that compared with the control group, levels of triglyceride, apolipoprotein-A1, and apolipoprotein-B in early pregnancy were significantly higher in the CHD group. Multivariate analyses showed that triglyceride (odds ratio [OR] 2.46), total/high-density lipoprotein cholesterol (OR 2.10), and apolipoprotein-A1 (OR 2.73), were positively associated with CHD risk in offspring. Each lipid biomarker was associated with an almost twofold increased risk of CHD, independent of HbA1c and Hcy.

The authors concluded that mild dyslipidemia in early pregnancy was closely associated with the occurrence of CHD in offspring. In combination with previous studies, it is possible that lipid metabolism in early pregnancy may influence the outcome of pregnancy. The study was published on August 3,2021 in the journal Acta Obstetricia et Gynecologica Scandinavica.

Related Links:

Children's Hospital of Fudan University
Hitachi 
Abbott
Applied Biosystems


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Glucose Tolerance Test
NERL Trutol
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.